Yahoo Finance

Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB ...

Hemab also unveiled compelling preclinical data for HMB-002, a potential novel treatment for Von Willebrand Disease (VWD). These data were featured as oral presentations at the 18th Annual Congress of ...
WKRN-TV

Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia

HMB-001 is a novel bispecific antibody designed to be the first prophylactic treatment for Glanzmann Thrombasthenia (GT) and other debilitating bleeding disorders Phase 1 was successfully completed in ...
Fox 5 San Diego

Hemab Therapeutics to Present New Preclinical Data on HMB-001 in Factor VII Deficiency and Initial Findings from Glanzmann Thrombasthenia Natural History Study at the ...

HMB-001 is currently in Phase 1/2 clinical study for Glanzmann Thrombasthenia—early research supports its potential expansion into Factor VII Deficiency COPENHAGEN, Denmark and BOSTON, June 15, 2023 ...
FOX8 Cleveland

Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia

CEO Benny Sorensen, MD, PhD, delivered the update during a corporate overview presented at the 41 st Annual JP Morgan Healthcare Conference "HMB-001 is the first candidate of our emerging pipeline to ...